Janssen Strikes US$3.75 B RNAi Partnership with Arrowhead
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 10 (Table of Contents)
Published: 13 Oct-2018
DOI: 10.3833/pdr.v2018.i10.2363 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Following the discontinuation of its EX1 drug delivery platform, Arrowhead Pharmaceuticals has come back with its Targeted RNAi Molecule (TRiM™) technology and signed a two-part deal with Janssen Pharmaceuticals worth potentially US$3...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS